Optimal positive cutoff points for careHPV testing of clinician- and self-collected specimens in primary cervical cancer screening: An analysis from rural China

Journal of Clinical Microbiology

Volumn 52, Issue 6, 2014, Pages 1954-1961

  Kang, Le Ni ^a   Jeronimo, Jose ^b   Qiao, You Lin ^a   Zhao, Fang Hui ^a   Chen, Wen ^a   Valdez, Melissa ^b   Zhang, Xun ^a   Bansil, Pooja ^b   Paul, Proma ^b   Bai, Ping ^a   Peck, Roger ^b   Li, Jing ^a   Chen, Feng ^a   Stoler, Mark H ^c   Castle, Philip E ^d  

^a CANCER HOSPITAL   (China)

^b PATH   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d Global Cancer Initiative   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; CHINA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RURAL POPULATION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; EARLY DIAGNOSIS; EVALUATION STUDY; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; MIDDLE AGED; MOLECULAR DIAGNOSIS; PAPILLOMAVIRIDAE; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADULT; AGED; CHINA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; RURAL POPULATION; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; UTERINE CERVICAL NEOPLASMS;

EID: 84901650520     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03432-13     Document Type: Article

References (32)

1. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL, Canadian Cervical Cancer Screening Trial Study Group. 2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357: 1579-1588. http://dx.doi.org/ 10.1056/NEJMoa071430 (Pubitemid 47598400)
2. Sankaranarayanan R, Budukh AM, Rajkumar R. 2001. Effective screening programmes for cervical cancer in low-and middle-income developing countries. Bull. World Health Organ. 79:954-962 (Pubitemid 33027175)
3. Denny L, Sankaranarayanan R. 2006. Secondary prevention of cervical cancer. Int. J. Gynecol. Obstet. 94:S65-S70. http://dx.doi.org/10.1016/S0020- 7292(07)60012-5
4. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ. 2012. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 13:78-88. http://dx.doi.org/10.1016/S1470-2045(11)70296-0
5. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J, New Technologies for Cervical Cancer screening (NTCC) Working Group. 2010. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11:249-257. http://dx.doi.org/10.1016/S1470-2045(09)70360-2
6. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. 2009. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360:1385-1394. http://dx.doi.org/10. 1056/NEJMoa0808516
7. Lorenzi AT, Fregnani JH, Possati-Resende JC, Neto CS, Villa LL, Longatto-Filho A. 2013. Self-collection for high-risk HPV detection in Brazilian women using the careHPVTM test. Gynecol. Oncol. 131:131-134. http://dx.doi.org/10.1016/j.ygyno.2013.07.092
8. Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, Weigl B, Zhang WH, Peck RB, Li L, Chen F, Pan QJ, Lorincz AT. 2008. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 9:929-936. http://dx.doi.org/10. 1016/S1470-2045(08)70210-9
9. Zhao FH, Jeronimo J, Qiao YL, Schweizer J, Chen W, Valdez M, Lu P, Zhang X, Kang LN, Bansil P, Paul P, Mahoney C, Berard-Bergery M, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE. 2013. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev. Res. 6:938-948. http://dx.doi.org/10.1158/1940-6207.CAPR-13-0091
10. Gage JC, Ajenifuja KO, Wentzensen N, Adepiti AC, Stoler M, Eder PS, Bell L, Shrestha N, Eklund C, Reilly M, Hutchinson M, Wacholder S, Castle PE, Burk RD, Schiffman M. 2012. Effectiveness of a simple rapid human papillomavirusDNAtest in rural Nigeria. Int. J. Cancer 131:2903-2909. http://dx.doi.org/10.1002/ijc.27563
11. Ngou J, Magooa MP, Gilham C, Djigma F, Didelot MN, Kelly H, Yonli A, Sawadogo B, Lewis DA, Delany-Moretlwe S, Mayaud P, Segondy M, HARP Study Group. 2013. Comparison of careHPV and hybrid capture 2 assays for detection of high-risk human papillomavirus DNA in cervical samples from HIV-1-infected African women. J. Clin. Microbiol. 51: 4240-4242. http://dx.doi.org/10.1128/JCM. 02144-13
12. Trope LA, Chumworathayi B, Blumenthal PD. 2013. Feasibility of community-based careHPV for cervical cancer prevention in rural Thailand. J. Low. Genit. Tract Dis. 17:315-319. http://dx.doi.org/10.1097/LGT. 0b013e31826b7b70
13. Levin CE, Sellors J, Shi JF, Ma L, Qiao YL, Ortendahl J, O?Shea MK, Goldie SJ. 2010. Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int. J. Cancer 127:1404-1411. http://dx.doi.org/10.1002/ijc .25150
14. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. 2001. Human papillomavirus testing in primary screening for the detection of highgrade cervical lesions: a study of 7932 women. Br. J. Cancer 84:1616-1623. http://dx.doi.org/10.1054/bjoc. 2001.1845 (Pubitemid 32612492)
15. Kulmala SM, Syrjänen S, Shabalova I, Petrovichev N, Kozachenko V, Podistov J, Ivanchenko O, Zakharenko S, Nerovjna R, Kljukina L, Branovskaja M, Grunberga V, Juschenko A, Tosi P, Santopietro R, Syrjänen K. 2004. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. J. Clin. Microbiol. 42:2470-2475. http://dx.doi.org/10.1128/JCM.42.6. 2470-2475.2004 (Pubitemid 38747492)
16. Sargent A, Bailey A, Turner A, Almonte M, Gilham C, Baysson H, Peto J, Roberts C, Thomson C, Desai M, Mather J, Kitchener H. 2010. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J. Clin. Microbiol. 48:554-558. http://dx.doi.org/10. 1128/JCM.00896-09
17. Zhao FH, Lewkowitz AK, Chen F, Lin MJ, Hu SY, Zhang X, Pan QJ, Ma JF, Niyazi M, Li CQ, Li SM, Smith JS, Belinson JL, Qiao YL, Castle PE. 2012. Pooled analysis of a self-sampling HPVDNAtest as a cervical cancer primary screening method. J. Natl. Cancer Inst. 104:178-188. http://dx.doi.org/10.1093/jnci/djr532
18. Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, Minozzi S, Bellisario C, Banzi R, Zhao FH, Hillemanns P, Anttila A. 2014. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 15:172-183. http://dx.doi.org/10.1016/S1470-2045(13)70570-9
19. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E, Nevarez PH, Acosta RD, Hernández-Avila M. 2011. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 378:1868-1873. http://dx.doi.org/10.1016/S0140-6736(11)61522-5
20. Lorincz A, Castanon A, Wey Lim AW, Sasieni P. 2013. New strategies for human papillomavirus-based cervical screening. Womens Health 9:443-452
21. Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, Zhang X, Qiao YL. 2004. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am. J. Obstet. Gynecol. 191:430-434. http://dx.doi.org/10.1016/j.ajog.2004.02. 065 (Pubitemid 39178694)
22. Garcia F, Barker B, Santos C, Brown EM, Nuño T, Giuliano A, Davis J. 2003. Cross-sectional study of patient-and physician-collected cervical cytology and human papillomavirus. Obstet. Gynecol. 102:266-272. http://dx.doi.org/10.1016/S0029-7844(03)00517-9 (Pubitemid 36936997)
23. Sellors JW, Lorincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P, Howard M, Chong S, Daya D, Chapman W, Chernesky M. 2000. Comparison of self-collected vaginal, vulvar, and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. CMAJ 163:513-518
24. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS, Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER, American Cancer Society, American Society for Colposcopy and Cervical Pathology, American Society for Clinical Pathology. 2012. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am. J. Clin. Pathol. 137:516-542. http://dx.doi.org/10.1309/ AJCPTGD94EVRSJCG.
25. Leeflang MM, Bossuyt PM, Irwig L. 2009. Diagnostic test accuracy may vary with prevalence: implications for evidence-based diagnosis. J. Clin. Epidemiol. 62:5-12. http://dx.doi.org/10.1016/j.jclinepi.2008.04.007
26. Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, Sellors JW, Franceschi S, Qiao YL, Castle PE, Cervical Cancer Screening Group in China. 2010. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 11:1160-1171. http://dx.doi.org/10.1016/S1470-2045(10)70256-4
27. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. 2007. Human papillomavirus and cervical cancer. Lancet 370:890-907. http://dx.doi.org/10.1016/S0140-6736(07)61416-0 (Pubitemid 47371147)
28. Lai CH, Chao A, Chang CJ, Chao FY, Huang HJ, Hsueh S, Lin CT, Cheng HH, Huang CC, Yang JE, Wu TI, Chou HH, Chang TC. 2008. Host and viral factors in relation to clearance of human papillomavirus infection: a cohort study in Taiwan. Int. J. Cancer 123:1685-1692. http://dx.doi.org/10.1002/ijc.23679
29. Giard RWM, Hermans J. 1996. The diagnostic information of tests for the detection of cancer: the usefulness of the likelihood ratio concept. Eur. J. Cancer 32A:2042-2048. http://dx.doi.org/10.1016/S0959-8049(96)00282-1 (Pubitemid 26419450)
30. McGee S. 2002. Simplifying likelihood ratios. J. Gen. Intern. Med. 17: 646-649
31. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124:516-520. http://dx.doi.org/10.1002/ijc.24010
32. Wright TC, Jr, Schiffman M. 2003. Adding a test for human papillomavirus DNA to cervical-cancer screening. N. Engl. J. Med. 348:489-490. http://dx.doi.org/10.1056/NEJMp020178.